» Authors » F Bozzi

F Bozzi

Explore the profile of F Bozzi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 20
Citations 688
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Busico A, Gasparini P, Rausa E, Cattaneo L, Bozzi F, Silvestri M, et al.
Sci Rep . 2024 Jun; 14(1):13138. PMID: 38849509
Colorectal cancer (CRC) is a global health concern, and the incidence of early onset (EO) CRC, has an upward trend. This study delves into the genomic landscape of EO-CRC, specifically...
2.
Uboldi S, Craparotta I, Colella G, Ronchetti E, Beltrame L, Vicario S, et al.
BMC Cancer . 2017 Feb; 17(1):107. PMID: 28166781
Background: Desmoplastic small round cell tumor (DSRCT) is a rare and highly aggressive disease, that can be described as a member of the family of small round blue cell tumors....
3.
Stacchiotti S, Tortoreto M, Bozzi F, Tamborini E, Morosi C, Messina A, et al.
Clin Cancer Res . 2013 Jul; 19(18):5192-201. PMID: 23888069
Purpose: To explore the value of triazines in solitary fibrous tumor (SFT). Experimental Design: We retrospectively reviewed 8 cases of patients with SFT treated with dacarbazine (1,200 mg/m(2) every 3...
4.
Stacchiotti S, Tamborini E, Vullo S, Bozzi F, Messina A, Morosi C, et al.
Ann Oncol . 2013 Apr; 24(7):1931-1936. PMID: 23559153
Background: To report on a prospective, investigator-driven, phase II study on lapatinib in epidermal growth factor receptor (EGFR)-positive advanced chordoma patients. Patients And Methods: From December 2009 to January 2012,...
5.
Stacchiotti S, Negri T, Zaffaroni N, Palassini E, Morosi C, Brich S, et al.
Ann Oncol . 2011 Jan; 22(7):1682-1690. PMID: 21242589
Background: The purpose of this study was to confirm sunitinib activity in alveolar soft part sarcoma (ASPS) and to report on new insights into the molecular bases thereof. Patients And...
6.
Negri T, Bozzi F, Conca E, Brich S, Gronchi A, Bertulli R, et al.
J Pathol . 2008 Nov; 217(1):103-12. PMID: 18973210
As the range of receptor tyrosine kinase (RTK) inhibitors widens, a detailed understanding of the activating mechanisms of KIT/platelet-derived growth factor receptor (PDGFR)A and the related downstream pathways involved in...
7.
Luksch R, Podda M, Gandola L, Polastri D, Piva L, Castellani R, et al.
Br J Cancer . 2005 May; 92(11):1984-8. PMID: 15900298
The aim of the present study was to evaluate the effectiveness of two consecutive nonrandomised treatment programs applied between 1989 and 1999 at the Istituto Nazionale Tumori of Milan in...
8.
Villa A, Sobacchi C, Notarangelo L, Bozzi F, Abinun M, Abrahamsen T, et al.
Blood . 2001 Jan; 97(1):81-8. PMID: 11133745
Severe combined immunodeficiency (SCID) comprises a heterogeneous group of primary immunodeficiencies, a proportion of which are due to mutations in either of the 2 recombination activating genes (RAG)-1 and -2,...
9.
Santagata S, Gomez C, Sobacchi C, Bozzi F, Abinun M, Pasic S, et al.
Proc Natl Acad Sci U S A . 2000 Dec; 97(26):14572-7. PMID: 11121059
Omenn's syndrome is an autosomal recessive primary immunodeficiency characterized by variable numbers of T lymphocytes of limited clonality, hypereosinophilia, and high IgE levels with a paradoxical absence of circulating B...
10.
Gomez C, Ptaszek L, Villa A, Bozzi F, Sobacchi C, Brooks E, et al.
Mol Cell Biol . 2000 Jul; 20(15):5653-64. PMID: 10891502
The V(D)J recombination reaction is composed of multiple nucleolytic processing steps mediated by the recombination-activating proteins RAG1 and RAG2. Sequence analysis has suggested that RAG2 contains six kelch repeat motifs...